Updated Jul 16, 2026
Tardugno Michael H has filed 5 SEC Form 4 filings across 1 company in the last 90 days.
Michael H. Tardugno is the Executive Chairman of the Board and a Director at Imunon, Inc., a clinical-stage biotechnology company. He has been involved in the company's strategic direction and oversight, particularly in advancing its DNA-based immunotherapy programs.
| Role | Executive Chairman of Board, Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-07 | IMNN | Imunon, Inc. | A — Grant or award | 4.4K | $1.91 | $8K |
| 2026-06-29 | IMNN | Imunon, Inc. | A — Grant or award | 42.5K | $1.72 | $73K |
| 2026-06-23 | IMNN | Imunon, Inc. | A — Grant or award | 4.6K | $1.82 | $8K |
| 2026-06-09 | IMNN | Imunon, Inc. | A — Grant or award | 4.1K | $2.06 | $8K |
| 2026-05-27 | IMNN | Imunon, Inc. | A — Grant or award | 3.5K | $2.20 | $8K |
Michael H. Tardugno is the Executive Chairman of the Board and a Director at Imunon, Inc., a clinical-stage biotechnology company. He has been involved in the company's strategic direction and oversight, particularly in advancing its DNA-based immunotherapy programs.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Tardugno Michael H profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.